Benzimidazole derivatives as tubulin polymerization inhibitors : Design, synthesis and in vitro cytotoxicity studies
Copyright © 2023 Elsevier Ltd. All rights reserved..
A new class of benzimidazole derivatives as tubulin polymerization inhibitors has been designed and synthesized in this study. The in vitro anticancer profile of the developed molecules was reconnoitred on selected human cancer cells. The highest cytotoxicity was illustrated by compounds 7n and 7u with IC50 values ranging from 2.55 to 17.89 µM with specificity toward SK-Mel-28 cells. They displayed 5-fold less cytotoxicity towards normal rat kidney epithelial NRK52E cells, which implies that they are not harmful to normal, healthy cells. The cellular staining procedures like AO/EB, DCFDA, and DAPI were applied to comprehend the inherent mechanism of apoptosis which displayed nuclear and morphological alterations. The Annexin V binding and JC-1 studies were executed to evaluate the extent of apoptosis and the decline in mitochondrial transmembrane potential in SK-Mel-28 cell lines. Compound 7n dose-dependently arrested the G2/M phase of the cell cycle and the target-based outcomes proposed tubulin polymerization inhibition by 7n (IC50 of 5.05±0.13 μM). Computational studies were also conducted on the tubulin protein (PDB ID: 3E22) to investigate the stabilized binding interactions of compounds 7n and 7u with tubulin, respectively.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:96 |
|---|---|
| Enthalten in: |
Bioorganic & medicinal chemistry letters - 96(2023) vom: 15. Nov., Seite 129494 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Laxmikeshav, Kritika [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 20.11.2023 Date Revised 20.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.bmcl.2023.129494 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362914524 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362914524 | ||
| 003 | DE-627 | ||
| 005 | 20231226092233.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bmcl.2023.129494 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1209.xml |
| 035 | |a (DE-627)NLM362914524 | ||
| 035 | |a (NLM)37797804 | ||
| 035 | |a (PII)S0960-894X(23)00372-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Laxmikeshav, Kritika |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Benzimidazole derivatives as tubulin polymerization inhibitors |b Design, synthesis and in vitro cytotoxicity studies |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.11.2023 | ||
| 500 | |a Date Revised 20.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Ltd. All rights reserved. | ||
| 520 | |a A new class of benzimidazole derivatives as tubulin polymerization inhibitors has been designed and synthesized in this study. The in vitro anticancer profile of the developed molecules was reconnoitred on selected human cancer cells. The highest cytotoxicity was illustrated by compounds 7n and 7u with IC50 values ranging from 2.55 to 17.89 µM with specificity toward SK-Mel-28 cells. They displayed 5-fold less cytotoxicity towards normal rat kidney epithelial NRK52E cells, which implies that they are not harmful to normal, healthy cells. The cellular staining procedures like AO/EB, DCFDA, and DAPI were applied to comprehend the inherent mechanism of apoptosis which displayed nuclear and morphological alterations. The Annexin V binding and JC-1 studies were executed to evaluate the extent of apoptosis and the decline in mitochondrial transmembrane potential in SK-Mel-28 cell lines. Compound 7n dose-dependently arrested the G2/M phase of the cell cycle and the target-based outcomes proposed tubulin polymerization inhibition by 7n (IC50 of 5.05±0.13 μM). Computational studies were also conducted on the tubulin protein (PDB ID: 3E22) to investigate the stabilized binding interactions of compounds 7n and 7u with tubulin, respectively | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Anti-cancer | |
| 650 | 4 | |a Benzimidazole | |
| 650 | 4 | |a Carboxamide | |
| 650 | 4 | |a Structure-activity relationship (SAR) | |
| 650 | 4 | |a Tubulin inhibition | |
| 650 | 7 | |a Tubulin Modulators |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Tubulin |2 NLM | |
| 650 | 7 | |a Benzimidazoles |2 NLM | |
| 700 | 1 | |a Rahman, Ziaur |e verfasserin |4 aut | |
| 700 | 1 | |a Mahale, Ashutosh |e verfasserin |4 aut | |
| 700 | 1 | |a Gurukkala Valapil, Durgesh |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Pravesh |e verfasserin |4 aut | |
| 700 | 1 | |a George, Joel |e verfasserin |4 aut | |
| 700 | 1 | |a Phanindranath, Regur |e verfasserin |4 aut | |
| 700 | 1 | |a Dandekar, Manoj P |e verfasserin |4 aut | |
| 700 | 1 | |a Kulkarni, Onkar P |e verfasserin |4 aut | |
| 700 | 1 | |a Nagesh, Narayana |e verfasserin |4 aut | |
| 700 | 1 | |a Shankaraiah, Nagula |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bioorganic & medicinal chemistry letters |d 1992 |g 96(2023) vom: 15. Nov., Seite 129494 |w (DE-627)NLM09063828X |x 1464-3405 |7 nnns |
| 773 | 1 | 8 | |g volume:96 |g year:2023 |g day:15 |g month:11 |g pages:129494 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bmcl.2023.129494 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 96 |j 2023 |b 15 |c 11 |h 129494 | ||